Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | RXRA | P19793 | 7/20 | 0.37 |
| ▸ | RXRB | P28702 | 6/20 | 0.37 |
| ▸ | RXRG | P48443 | 5/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12303640 | 0.84 | RET (0.54) | METKDRRET | |
| SCHEMBL2452688 | 0.84 | RET (0.54) | METKDRRET | |
| SCHEMBL2452685 | 0.84 | RET (0.54) | METKDRRET | |
| SCHEMBL2451345 | 0.75 | KDR (0.43) | ALDH1A1TP53SMN1; SMN2MAPTKDR | |
| SCHEMBL2453270 | 0.74 | KDM1A (0.47) | ALDH1A1TP53SMN1; SMN2MAPTKDR | |
| SCHEMBL1095145 | 0.73 | EGFR (0.57) | ALDH1A1SMN1; SMN2EGFR | |
| SCHEMBL2455070 | 0.71 | LMNA (0.47) | ALDH1A1TP53SMN1; SMN2MAPT | |
| SCHEMBL13019936 | 0.71 | SRC (0.46) | ALDH1A1SMN1; SMN2KDRRETEGFR | |
| SCHEMBL31312989 | 0.70 | BCL2L1 (0.54) | SMN1; SMN2RXRARXRBRXRGBRAF | |
| SCHEMBL2451183 | 0.70 | LMNA (0.41) | ALDH1A1TP53SMN1; SMN2SCN9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8013153-B2 | Substituted pyrimidine kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2011-09-06 | — | — | US | disclosed |
| US-20070254896-A1 | SUBSTITUTED PYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254896-A1 | SUBSTITUTED PYRIMIDINE KINASE INHIBITORS | DTYMK, TK1, DCK | ALDH1A1 2496/4885TP53 999/4885SMN1; SMN2 2628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.